What Matthew Perry's death can and cannot tell us about ketamine therapy

Since the sentencing last week, I have heard from patients who are frightened, families who are confused, and people who were finally considering treatment and are now pulling back. I want to address this carefully.

Matthew Perry died because of ketamine. That is true, and it deserves to be said plainly. What is also true is that what happened to him in the final weeks of his life had no meaningful resemblance to how ketamine is used in a responsible clinical setting. Those two facts need to be held together, because collapsing them is causing real harm to people who are already struggling.

Perry had been in legitimate ketamine infusion therapy for depression and anxiety. His last supervised clinical session was more than a week before he died. In between, he had developed a severe addiction to the drug, obtaining it through an underground network of dealers and physicians willing to supply whatever he was willing to pay for. His personal assistant, who had no medical training, was injecting him six to eight times a day. The level of ketamine in his blood at autopsy was consistent with full surgical anesthesia. There was no monitoring, no oversight, no clinical structure of any kind. Five people have now pleaded guilty to federal charges related to his death.

That is not a treatment story. That is an addiction story and a story about exploitation.

What ketamine actually does in the brain

Ketamine has been FDA-approved as a surgical anesthetic since 1970 and has been used safely in clinical settings for over fifty years. It works on NMDA receptors, which are involved in synaptic plasticity, mood regulation, and how the brain processes threat and pain. That mechanism turns out to be clinically significant in a way that was not appreciated until relatively recently.

Traditional antidepressants work on serotonin and norepinephrine systems and take weeks to build therapeutic effect. Ketamine produces antidepressant effects within hours of a single dose. For someone who has been through multiple medication trials without meaningful relief, that is not a small thing. It also has a measurable effect on suicidal ideation specifically, which is an area where psychiatry has historically had very limited tools. The ability to reduce acute suicidal thinking quickly has real clinical value, and the evidence base behind it is substantial and spans decades of research.

One pharmacological point worth knowing: unlike opioids, ketamine does not suppress respiratory drive. In a properly monitored clinical setting, fatal overdose from ketamine alone is considered extremely unlikely. This is part of why it has been used safely in emergency medicine for so long.

The three forms of treatment, and why the differences matter

When people hear about ketamine therapy, they are often not aware that there are meaningfully different forms of it. Intravenous infusion is the most extensively studied form. It is administered through an IV over 40 to 60 minutes in a clinical setting, typically as a series of six infusions over two to three weeks, with maintenance sessions as clinically indicated. It is used off-label, meaning it is not FDA-approved specifically for depression, though the evidence supporting its use is strong. It is rarely covered by insurance and requires continuous monitoring throughout each session.

Spravato, the brand name for esketamine, is a nasal spray and the only FDA-approved ketamine-based treatment for depression. It is a purified component of the ketamine molecule administered in a certified healthcare setting, never at home. Patients remain on-site for two hours after each dose for monitoring. It is FDA-approved specifically for treatment-resistant depression and for major depressive disorder with active suicidal ideation, and it is frequently covered by insurance.

Ketamine-assisted psychotherapy, or KAP, integrates a ketamine dose with structured psychotherapy conducted before, during, and after the dosing experience. A trained therapist works with the patient to facilitate psychological processing during the window the ketamine creates. This requires close collaboration between a prescribing clinician and a therapist and, in my view, represents the most complete form of ketamine-informed care for many patients. The evidence base is growing and genuinely compelling.

Is ketamine addictive? The honest answer.

Yes. Ketamine has real abuse potential, and I am not going to minimize that, particularly given what we all just watched happen.

Ketamine produces dissociative effects that some people find powerfully compelling. Psychological dependence, a compulsive craving of the dissociative experience itself, is the primary addiction risk. Tolerance develops with repeated use, which drives escalating frequency and dose. Physical dependence with withdrawal symptoms is less common than with opioids or alcohol, but the psychological dependence can be significant and destabilizing. The risk is meaningfully higher in people with a prior history of substance use disorder, unmanaged psychiatric illness, or trauma history, and it rises sharply the moment access moves outside a controlled clinical setting.

In well-designed clinical programs with rigorous patient selection, defined dosing intervals, active monitoring, and integrated psychotherapy, the rate of problematic use is low. The structure is not incidental to the safety. It is the safety. Remove it, and the risk profile changes fundamentally.

Perry had a well-documented addiction history spanning decades. He wrote about it honestly in his memoir, published the year before he died. Someone with that history can still be a candidate for ketamine therapy, but it requires extra caution, more conservative dosing, more frequent clinical contact, and a treatment team that is specifically watching for signs of escalation. The failure in his case was not that he received ketamine. The failure was that the clinical structure necessary to treat someone with his history safely was entirely absent by the time he died.

What responsible treatment looks like, and why it matters

As ketamine clinics have proliferated, so has significant variation in the quality of care. Not every clinic offering ketamine therapy is offering the same level of clinical rigor, and patients deserve to understand what they should expect from a responsible provider.

Responsible ketamine treatment begins with a comprehensive psychiatric evaluation that includes a detailed substance use history and a genuine clinical determination of whether ketamine is appropriate for this particular patient. It requires a licensed prescriber with mental health training making that decision. It involves standardized dosing based on clinical indication, body weight, and treatment history, not patient preference or requests for more. Every session should include continuous monitoring, including vital signs and ongoing mental status assessment, and a post-session observation period before the patient leaves. Integration therapy, meaning structured psychotherapy that contextualizes and builds on what emerges during treatment, should be part of the protocol. The treatment plan should have clear goals, an expected duration, and explicit criteria for continuing, pausing, or stopping. And there should be no take-home doses, under any circumstances.

When I evaluate a patient for ketamine therapy, I am asking two questions simultaneously: whether they are likely to benefit, and whether the safeguards I can provide are matched to the risk they carry. Both questions have to have satisfactory answers before treatment begins.

What I want patients to take from this

If you have been living with depression that has not responded to standard treatment, with PTSD, or with suicidal thinking that keeps returning despite medication, ketamine therapy is a legitimate, evidence-based option worth a serious clinical conversation. The research is real. The FDA approval of Spravato reflects rigorous study. The patients I have seen respond to this treatment, people for whom nothing else worked, are not abstractions.

Perry's story should make us more demanding of the providers and systems offering this treatment, more attentive to the complexity of treating patients with co-occurring addiction histories, and more honest about how quickly a therapeutic relationship can become something harmful when accountability disappears. It should not cause patients who genuinely need help to walk away from a treatment that might give it to them.

If you have questions about whether any form of ketamine therapy is appropriate for your situation, I am glad to have that conversation. Careful, individualized evaluation is exactly what this treatment requires.